Revance Therapeutics Intrinsic Value Calculation – REVANCE THERAPEUTICS Reports Q2 2023 Earnings on August 8, 2023

August 15, 2023

🌥️Earnings Overview

On August 8, 2023, REVANCE THERAPEUTICS ($NASDAQ:RVNC) released its financial results for the second quarter of 2023 (ending June 30, 2023). Total revenue experienced a 104.9% year-over-year increase, amounting to USD 58.1 million. Net income reported was USD -67.3 million, a slight decrease from the -61.4 million reported in the same quarter in the previous year.

Market Price

On Tuesday, August 8th, 2023, REVANCE THERAPEUTICS reported its second quarter earnings for the fiscal year. The stock opened at $21.6, up 1.3% from its previous closing price of $21.7. Throughout the day, the stock gained additional value and closed at $22.0. As a result, the company’s net income is expected to increase over the course of the year. The financial performance of REVANCE THERAPEUTICS has been largely attributed to the company’s recent advances in drug development, potential partnerships with other pharmaceutical companies, and new products released over the past year.

These developments have put REVANCE THERAPEUTICS in a favorable position for further growth throughout the remainder of the fiscal year. Overall, investors have responded positively to REVANCE THERAPEUTICS’ second-quarter earnings report, making it clear that the company has a bright future ahead. Many believe that the stock will continue to rise as the company continues to make advancements in its drug development and product offerings. Live Quote…

About the Company

  • Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Revance Therapeutics. More…

    Total Revenues Net Income Net Margin
    186.4 -357.07 -169.1%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Revance Therapeutics. More…

    Operations Investing Financing
    -210.94 -21.7 305.95
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Revance Therapeutics. More…

    Total Assets Total Liabilities Book Value Per Share
    597.53 570.75 0.32
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Revance Therapeutics are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    623.6% -181.1%
    FCF Margin ROE ROA
    -125.3% -373365.0% -35.3%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items
  • Analysis – Revance Therapeutics Intrinsic Value Calculation

    At GoodWhale, we recently conducted an analysis of REVANCE THERAPEUTICS‘s wellbeing. After taking into account various factors such as the company’s financial statements, industry trends, management performance and future prospects, we have determined that the intrinsic value of REVANCE THERAPEUTICS shares is around $65.1. This figure was calculated using our proprietary Valuation Line platform. Currently, REVANCE THERAPEUTICS shares are trading at $22.0, which represents an undervaluation of 66.2%. This presents a unique opportunity for investors looking to capitalize on the market’s undervaluation of REVANCE THERAPEUTICS. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis

  • Peers

    In the realm of aesthetic treatments, there is fierce competition among companies to develop the most innovative and effective products. Among these companies is Revance Therapeutics Inc, which is up against tough competition from Viva Biotech Holdings, Pharmaron Beijing Co Ltd, and CStone Pharmaceuticals. All of these companies are vying to create the best products and treatments that will appeal to consumers.

    – Viva Biotech Holdings ($SEHK:01873)

    Viva Biotech Holdings is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for the treatment of various diseases. The company’s lead product candidate is VB-111, a first-in-class, targeted anti-cancer agent that is in Phase III clinical development for the treatment of glioblastoma, the most common and aggressive form of brain cancer. Viva Biotech has a market cap of 2.28B as of 2022 and a Return on Equity of 5.39%.

    – Pharmaron Beijing Co Ltd ($SZSE:300759)

    Pharmaron Beijing Co., Ltd. is a global, research-based drug discovery and development company that partners with life science organizations to transform the way therapeutics are discovered and developed. The company’s services include target identification and validation, lead optimization, preclinical and clinical research, and commercialization. Pharmaron Beijing Co., Ltd. is headquartered in Beijing, China.

    – CStone Pharmaceuticals ($OTCPK:CSPHF)

    CStone Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of innovative immuno-oncology therapeutics. The company’s market cap is 508.8M as of 2022 and its ROE is -87.18%. CStone Pharmaceuticals is focused on developing and commercializing immuno-oncology therapies that target the tumor microenvironment and modulate the immune system to fight cancer. The company’s lead product candidate, CS1001, is a PD-L1/TGF-β inhibitor that is being evaluated in a global Phase III clinical trial in first-line non-small cell lung cancer.


    Investors should closely monitor the financial performance of REVANCE THERAPEUTICS as the company released their second quarter earnings for FY2023 on August 8, 2023. Revenue grew by 104.9% year-over-year, reaching USD 58.1 million, however, net income reported for the quarter was USD -67.3 million, down from -61.4 million in the same period last year. Despite strong revenue growth, investors must be aware of the net loss and consider other factors such as cash flow, profitability, and balance sheet strength when evaluating REVANCE THERAPEUTICS as an investment opportunity.

    Recent Posts

    Leave a Comment